Investigation of syphilis immunology and Treponema pallidum subsp. pallidum biology to improve clinical management and design a broadly protective vaccine: study protocol
- PMID: 32576149
- PMCID: PMC7309211
- DOI: 10.1186/s12879-020-05141-0
Investigation of syphilis immunology and Treponema pallidum subsp. pallidum biology to improve clinical management and design a broadly protective vaccine: study protocol
Abstract
Background: The syphilis epidemic continues to cause substantial morbidity and mortality worldwide, particularly in low- and middle-income countries, despite several recent disease control initiatives. Though our understanding of the pathogenesis of this disease and the biology of the syphilis agent, Treponema pallidum subsp. pallidum has improved over the last two decades, further research is necessary to improve clinical diagnosis and disease management protocols. Additionally, such research efforts could contribute to the identification of possible targets for the development of an effective vaccine to stem syphilis spread.
Methods: This study will recruit two cohorts of participants with active syphilis infection, one with de novo infection, one with repeat infection. Whole blood specimens will be collected from each study participant at baseline, 4, 12, 24, 36, and 48 weeks, to track specific markers of their immunological response, as well as to compare humoral reactivity to Treponema pallidum antigens between the two groups. Additionally, we will use serum specimens to look for unique cytokine patterns in participants with early syphilis. Oral and blood samples, as well as samples from any syphilitic lesions present, will also be collected to sequence any Treponema pallidum DNA found.
Discussion: By furthering our understanding of syphilis pathogenesis and human host immune response to Treponema pallidum, we will provide important data that will help in development of new point-of-care tests that could better identify active infection, leading to improved syphilis diagnosis and management. Findings could also contribute to vaccine development efforts.
Keywords: Cytokine profiling; Molecular typing; Peru; Syphilis; Treponema pallidum; Vaccine development.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Non-pathogenic Borrelia burgdorferi expressing Treponema pallidum TprK and Tp0435 antigens as a novel approach to evaluate syphilis vaccine candidates.Vaccine. 2019 Mar 22;37(13):1807-1818. doi: 10.1016/j.vaccine.2019.02.022. Epub 2019 Feb 20. Vaccine. 2019. PMID: 30797635 Free PMC article.
-
Assessment of the immune responses to Treponema pallidum Gpd DNA vaccine adjuvanted with IL-2 and chitosan nanoparticles before and after Treponema pallidum challenge in rabbits.Sci China Life Sci. 2013 Feb;56(2):174-80. doi: 10.1007/s11427-012-4434-4. Epub 2013 Jan 18. Sci China Life Sci. 2013. PMID: 23334700
-
Polypeptides of Treponema pallidum: progress toward understanding their structural, functional, and immunologic roles. Treponema Pallidum Polypeptide Research Group.Microbiol Rev. 1993 Sep;57(3):750-79. doi: 10.1128/mr.57.3.750-779.1993. Microbiol Rev. 1993. PMID: 8246847 Free PMC article. Review.
-
A defined syphilis vaccine candidate inhibits dissemination of Treponema pallidum subspecies pallidum.Nat Commun. 2017 Feb 1;8:14273. doi: 10.1038/ncomms14273. Nat Commun. 2017. PMID: 28145405 Free PMC article.
-
Progress towards an effective syphilis vaccine: the past, present and future.Expert Rev Vaccines. 2006 Feb;5(1):67-80. doi: 10.1586/14760584.5.1.67. Expert Rev Vaccines. 2006. PMID: 16451109 Review.
Cited by
-
Molecular Characterization of Genital and Extragenital Lesions With the PlexPCR VHS Assay in Patients Diagnosed With Syphilis.Open Forum Infect Dis. 2023 Sep 26;10(10):ofad483. doi: 10.1093/ofid/ofad483. eCollection 2023 Oct. Open Forum Infect Dis. 2023. PMID: 37869408 Free PMC article.
-
Syphilis-Naive Patients Achieve Treatment Success More Quickly: A Comparison of Time to Syphilis Treatment Success in Patients With Repeat Versus Naive Infection.Clin Infect Dis. 2022 May 30;74(10):1887-1888. doi: 10.1093/cid/ciab877. Clin Infect Dis. 2022. PMID: 34596682 Free PMC article. No abstract available.
-
Fascinating Molecular and Immune Escape Mechanisms in the Treatment of STIs (Syphilis, Gonorrhea, Chlamydia, and Herpes Simplex).Int J Mol Sci. 2022 Mar 24;23(7):3550. doi: 10.3390/ijms23073550. Int J Mol Sci. 2022. PMID: 35408911 Free PMC article. Review.
-
HIV Infection Modifies the Role of Prior Treponema pallidum Infection in the Clinical Presentation of Early Syphilis Among Adult Patients From Sexually Transmitted Infection Clinics in Peru.Sex Transm Dis. 2024 Jun 1;51(6):415-419. doi: 10.1097/OLQ.0000000000001950. Epub 2024 Feb 19. Sex Transm Dis. 2024. PMID: 38372543 Free PMC article.
References
-
- Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–1259. - PMC - PubMed
-
- Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2017. Atlanta: U.S. Department of Health and Human Services; 2018. 10.15620/cdc.59237.